リコンビネント・ヒューマン・ペントラキシン2とプラセボの作用 異症性肺線維症患者の強制生命能力の変化: ランダム化臨床試験
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。リコンビネントヒトペントラキシン2は,28週間の間,イディオパシー肺線維症 (IPF) の患者で肺機能の低下を遅らせました. この研究は,IPF治療の改善の可能性を示唆しています.
科学分野
- 肺医学
- 繊維性肺疾患
- 臨床試験
背景
- Idiopathic pulmonary fibrosis (IPF) は,予後が悪い進行する肺疾患である.
- IPFの現在の治療法では 病気の進行を止められません
研究 の 目的
- IPF患者におけるリコンビナントヒトペントラキシン2の有効性をプラセボと比較する.
- 28週間の強制生命力低下 (FVC) への影響を評価する.
主な方法
- IPF患者117人を対象としたランダム化,ダブルブラインド,プラセボ対照試験.
- 患者は24週間の間,リコンビナンスのヒトペントラキシン2 (10 mg/ kgIV) またはプラセボを投与された.
- 予期値のFVCパーセントの変化
主要な成果
- 再結合ヒトペントラキシン2は,予測値のFVC比率の低下が遅かった (-2. 5 対 - 4. 8; P=. 001).
- 6分の歩行距離で顕著な改善が見られた (差は+31. 3m,P < . 001).
- 肺の容量や一酸化炭素 (DLCO) の拡散能力の有意な差異は認められなかった.
結論
- 再結合ヒトペントラキシン2は,IPF患者における肺機能低下を遅らせる可能性を示した.
- この治療の有効性と安全性を完全に確立するために,さらなる研究が必要である.
- この予備的な研究は,IPF管理のための有望な治療法を示しています.
自動的に一致したビデオです Contact us もしそれらが関連していない場合
自動的に一致したビデオです Contact us もしそれらが関連していない場合
関連する概念動画
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
There are four defined lung volume measures: tidal volume, inspiratory reserve volume, expiratory reserve volume, and residual volume.
Tidal volume is the amount of air inhaled and exhaled in a normal breath. Inspiratory...
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
The placebo effect is commonly described in terms of testing the effectiveness of a new medication. Imagine that you work in a pharmaceutical company, and you think you have a new drug that is effective in treating depression. To demonstrate that your medication is effective, you run...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
Overview
Scientists create recombinant DNA by combining DNA from different sources—often, other species—in the laboratory. DNA cloning allows researchers to study specific genes by inserting them into easily manipulated cells, such as bacteria. Organisms that contain recombinant DNA are known as genetically modified organisms (GMOs). Recombinant DNA technology produces organisms with new genes that can benefit science, medicine, and agriculture.
How Do Scientists Create...